Phoenix Financial Ltd. Acquires New Shares in Biogen Inc. $BIIB

Phoenix Financial Ltd. acquired a new stake in Biogen Inc. (NASDAQ:BIIB) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,133 shares of the biotechnology company’s stock, valued at approximately $551,000.

Other hedge funds also recently bought and sold shares of the company. WPG Advisers LLC increased its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after buying an additional 117 shares in the last quarter. Accredited Wealth Management LLC increased its position in Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock worth $28,000 after buying an additional 185 shares in the last quarter. First Horizon Corp purchased a new position in Biogen during the fourth quarter worth $30,000. WFA of San Diego LLC purchased a new stake in shares of Biogen in the second quarter valued at $32,000. Finally, GoalVest Advisory LLC purchased a new stake in shares of Biogen in the fourth quarter valued at $35,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

BIIB opened at $192.95 on Friday. The stock has a fifty day moving average of $185.21 and a 200-day moving average of $179.33. The firm has a market capitalization of $28.49 billion, a P/E ratio of 20.70, a PEG ratio of 1.70 and a beta of 0.19. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $205.97. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities analysts forecast that Biogen Inc. will post 14.21 EPS for the current fiscal year.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen said its Phase 2 CELIA study of diranersen (BIIB080), a tau-targeting Alzheimer’s drug, showed robust reductions in tau pathology and signals of slowed cognitive decline, prompting the company to advance the program into late-stage development. Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
• Positive Sentiment: Goldman Sachs reiterated a Buy rating and lifted its price target to $250, while Oppenheimer raised its target to $300 and Evercore initiated coverage with an Outperform rating, reinforcing optimism around Biogen’s valuation and pipeline. Goldman’s Richter Reiterates Buy on Biogen as Leqembi Outperforms and Price Target Rises from $238 to $250 Oppenheimer raises Biogen price target to $300 from $275, maintains Outperform rating
• Positive Sentiment: Biogen completed its $5.3 billion acquisition of Apellis Pharmaceuticals, adding commercial products SYFOVRE and EMPAVELI and potentially improving near-term growth prospects. Biogen Completes Acquisition of Apellis Pharmaceuticals
• Neutral Sentiment: Some analysts remain cautious, saying mixed Alzheimer’s data and pipeline uncertainty still create a balanced risk/reward profile despite the recent rally. Biogen: Hold Rating Reiterated as Pipeline Concerns Offset Leqembi Growth; $196 Price Target Maintained
• Negative Sentiment: The CELIA study missed its primary endpoint, and a law firm has already announced an investigation into possible securities-law issues tied to the stock’s move after the data release, which could add headline risk. Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny – Contact Levi & Korsinsky for Details

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on BIIB shares. Barclays started coverage on Biogen in a research report on Thursday, February 19th. They issued an “equal weight” rating and a $185.00 target price for the company. Wolfe Research set a $231.00 target price on Biogen in a research report on Monday, February 9th. Royal Bank Of Canada boosted their price target on Biogen from $213.00 to $222.00 and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Guggenheim lifted their price objective on Biogen from $246.00 to $260.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Finally, TD Cowen increased their target price on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research note on Monday, February 9th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $215.62.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.